Malignant pleural mesothelioma is a rare, aggressive lung cancer that develops in the pleura, a thin layer of tissue surrounding the lungs. Approximately 3,000 people are diagnosed each year in the United States.
Response rates to chemotherapy are generally less than 40%.
Five-year survival rates are less than 20%.
Aldeyra’s chaperome inhibitors, in combination with DNA-damaging agents, may have utility in the treatment of cancers such as mesothelioma and ovarian cancer. The chaperome inhibitor system is required for DNA repair, and chaperome inhibition in the setting of DNA damage could lead to cancer cell death.